Research programme: bone disorder therapeutics - Osta

Drug Profile

Research programme: bone disorder therapeutics - Osta

Alternative Names: PTH 1-34

Latest Information Update: 18 Aug 2009

Price : $50

At a glance

  • Originator McGill University
  • Developer Osta Biotechnologies
  • Class
  • Mechanism of Action PHEX phosphate regulating neutral endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Osteoporosis; X-linked dominant hypophosphataemic rickets

Most Recent Events

  • 31 Mar 2009 Suspended - Preclinical for X-linked dominant hypophosphataemic rickets in Canada (PO)
  • 31 Mar 2009 Suspended - Preclinical for Osteoporosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top